FIELD: biotechnology.
SUBSTANCE: described is a method for propagation of virus-specific memory T-cells, involving the introduction of a virus-specific memory T-cell into contact with a binding protein, where the binding protein contains four polypeptide chains which form three antigen-binding sites. Described is a method for propagation of T-cells, involving the introduction of a T-cell into contact with a binding protein in vitro or ex vivo, where the binding protein contains four polypeptide chains which form three antigen-binding sites. Disclosed is a method of treating a chronic viral infection, comprising administering to a patient an effective amount of a binding protein, where the binding protein contains four polypeptide chains which form three antigen-binding sites.
EFFECT: invention extends the range of products for treating chronic viral infections.
31 cl, 13 dwg, 13 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
